Last updated: May 8, 2026
Who supplies bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride?
What are the drug substances and what is the likely procurement footprint?
The regimen ingredients map to three distinct drug substances (APIs or API-grade raw materials), each with a different supplier concentration profile:
- Bismuth subcitrate potassium (drug substance; bismuth salt)
- Metronidazole (drug substance; nitroimidazole)
- Tetracycline hydrochloride (drug substance; tetracycline-class antibiotic)
For business procurement, the practical footprint is: bismuth salts typically source from a smaller set of specialized inorganic/metal-salt producers; metronidazole and tetracycline APIs typically come from a broader global field of antibiotic API manufacturers with established GMP and DMF/CEP documentation workflows.
Which suppliers supply each drug substance?
Below are supplier sets that commonly produce these exact drug substances at commercial scale (API and/or intermediate), including multiple global GMP manufacturers that routinely support branded and generic solid oral products.
Bismuth subcitrate potassium (API / drug substance)
Common supplier profile includes manufacturers of bismuth salts and bismuth-containing APIs.
| Supplier |
Product line relevance |
What to validate in sourcing |
| BASF (through API/chemical manufacturing networks) |
Inorganics and pharmaceuticals supply chains |
GMP status for drug substance grade; DMF availability; specification sheet match |
| Zhejiang Hisun Pharmaceutical |
bismuth-based GI products and API supply capabilities |
Bismuth subcitrate potassium grade, polymorph control, heavy metals specs |
| Hikma / Accord supply-chain partners (via API outsourcing ecosystem) |
generic oral solid supply chains typically contract for GI APIs |
Local qualified-manufacturer list; COA lot traceability; regulatory filing link |
| China-based inorganic/pharma API producers (varied) |
bismuth salts and related API intermediates |
DMF/CEP, inspection history, residuals and assay range compliance |
Metronidazole (API / drug substance)
Metronidazole is a mature, high-volume nitroimidazole API. Supplier base is broad.
| Supplier |
Product line relevance |
What to validate in sourcing |
| Strides Pharma (formerly Strides Shasun) |
oral antibiotic API portfolio |
DMF status; particle size/grade for formulation; GMP inspection outcomes |
| Hetero Labs |
API manufacturing for antibiotics |
specification alignment (assay, water content, impurities) |
| Torreya / global nitroimidazole API makers (varied) |
nitroimidazole manufacturing capability |
nitroimidazole impurity profile; stability data |
| Accord / Teva supply-chain contract manufacturing |
generic manufacturing buys metronidazole APIs |
qualified supplier list; batch consistency and residual solvent specs |
Tetracycline hydrochloride (API / drug substance)
Tetracycline-class APIs are produced by a narrower group than metronidazole but still have multiple commercial GMP sources.
| Supplier |
Product line relevance |
What to validate in sourcing |
| Glenmark / contract manufacturing partners (via supply chain) |
antibiotics portfolio |
API impurity profile control; DMF or CEP |
| Hikma / generic supply-chain partners |
oral antibiotic manufacturing ecosystem |
salt form confirmation (hydrochloride), assay and impurity limits |
| China-based tetracycline API manufacturers (varied) |
tetracycline hydrochloride API production |
antibiotic-residue controls, cross-contamination mitigation, inspection history |
What supplier documentation to require for regulatory-ready procurement
Across all three APIs, procurement for high-stakes development (clinical or commercial) typically requires the same compliance set. Use it as a gating checklist:
- GMP confirmation: drug substance manufacturing site GMP certificate and current inspection status
- Regulatory dossier linkage: DMF letter and/or CEP (where applicable) for each drug substance
- Lot traceability: batch COA with unique lot identifier; stability commitment if used for bridging
- Specifications pack: assay, related substances/impurities, residual solvents, heavy metals (critical for bismuth salts), particle size for tablets/capsules
- Change control: notification process for manufacturing changes, scale changes, equipment changes, and cleaning validation updates
How to optimize supplier selection across the triple-API regimen
The three substances create a procurement structure that favors parallel qualification streams:
- Run three independent vendor paths: GI bismuth salt qualification does not transfer to antibiotic APIs.
- Prioritize regulatory alignment: the API filing strategy (DMF/CEP) often drives lead time more than price.
- Plan for formulation-driven grades: metronidazole and tetracycline hydrochloride can require different impurity profiles and physical attributes to hit dissolution and content-uniformity targets.
- Stress-test specification match: tetracycline hydrochloride is salt-form sensitive; bismuth subcitrate potassium is sensitive to heavy metals and assay/impurity ranges tied to bismuth chemistry.
Key Takeaways
- The regimen uses three distinct drug substances with different supplier concentrations: bismuth subcitrate potassium (bismuth salts) and two antibiotic APIs (metronidazole, tetracycline hydrochloride).
- Supplier selection should be driven by GMP/site documentation and dossier linkage (DMF/CEP), not just ability to quote a price.
- Qualification must be substance-specific: GI bismuth salt specs and impurity controls do not carry over to nitroimidazole or tetracycline APIs.
- Procurement success is about matching COA specs, dossier status, and formulation-relevant grades across all three materials.
FAQs
1) Are there multi-product suppliers for all three ingredients?
Some large pharma chemical suppliers can support multiple categories, but regulatory-ready supply typically still requires separate API-grade qualification for each drug substance (bismuth salt, metronidazole, tetracycline hydrochloride).
2) Which API is most sensitive for specification and impurity control?
Bismuth subcitrate potassium is typically the most sensitive to heavy-metals and inorganic impurity specifications; tetracycline hydrochloride is salt-form and antibiotic impurity sensitive; metronidazole is nitroimidazole impurity sensitive.
3) Does CEP/DMF availability matter for sourcing?
Yes. For regulatory submissions and rapid commercialization timelines, DMF/CEP linkage and consistency across suppliers is a primary determinant of feasibility.
4) What procurement risk is common with antibiotic APIs?
Cross-contamination risk, lot-to-lot impurity variability, and inspection-driven supplier continuity are common constraints that affect qualification timelines.
5) What is the most practical sourcing strategy?
Qualification in parallel for each drug substance with strict spec matching and dossier-aligned documentation, then locking lead suppliers by lot consistency and regulatory compatibility.
References
[1] European Directorate for the Quality of Medicines (EDQM). European Pharmacopoeia entries for metronidazole, tetracycline hydrochloride, and bismuth subcitrate potassium.
[2] U.S. Food and Drug Administration (FDA). Drug Master File (DMF) guidance and regulatory framework for drug substances.
[3] EMA. European Medicines Agency guidance on quality documentation for APIs (CEP/DMF, GMP, and variation controls).
